What is the appropriate medication regimen for an 82‑year‑old female with a recent non‑ST‑segment elevation myocardial infarction secondary to COVID‑19 and a chronic obstructive pulmonary disease exacerbation?

Medication Management for 82-Year-Old Female with Recent NSTEMI Secondary to COVID-19 and COPD Exacerbation

This patient requires dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor), high-intensity statin therapy targeting LDL-C <55 mg/dL, ACE inhibitor or ARB, beta-blocker, and prophylactic-dose anticoagulation during hospitalization, along with standard COPD exacerbation management including bronchodilators and corticosteroids.

Antiplatelet Therapy

Initiate dual antiplatelet therapy (DAPT) immediately with aspirin and a P2Y12 inhibitor for 12 months 1. For this 82-year-old patient with recent NSTEMI and COVID-19, the 2023 CHEST guidelines provide a strong recommendation for DAPT to reduce recurrent ACS or death 1.

• Aspirin: 81-325 mg loading dose, then 81 mg daily indefinitely
• P2Y12 inhibitor: Choose clopidogrel 75 mg daily (preferred in elderly due to lower bleeding risk) over ticagrelor or prasugrel given her age 2

Critical consideration: If she requires prophylactic-dose anticoagulation for COVID-19 during hospitalization, continue DAPT alongside it 1. However, if therapeutic-dose anticoagulation becomes necessary, individualize the decision weighing bleeding risk—at age 82, strongly consider dropping to single antiplatelet therapy (aspirin alone) 1.

Lipid Management

Start high-intensity statin therapy immediately targeting LDL-C reduction of ≥50% from baseline with goal <55 mg/dL (<1.4 mmol/L) 2. This is a class I recommendation for very high cardiovascular risk patients with ACS. Use atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily.

Cardioprotective Medications

ACE Inhibitor or ARB

Initiate an ACE inhibitor (or ARB if ACE-intolerant) given her recent NSTEMI 2. This is particularly important if she has:

• Left ventricular ejection fraction <40%
• Heart failure symptoms
• Diabetes or chronic kidney disease

Start with low doses (e.g., lisinopril 2.5-5 mg daily) and titrate upward, monitoring renal function and potassium closely given her age.

Beta-Blocker

Start a beta-blocker if she has systolic LV dysfunction (LVEF <40%) or heart failure 2. Use cardioselective agents (metoprolol succinate or bisoprolol) given her COPD—these are safer than non-selective beta-blockers. Start low (e.g., metoprolol succinate 25 mg daily) and titrate cautiously, monitoring for bronchospasm.

Important caveat: COPD is not an absolute contraindication to beta-blockers post-MI, but requires careful selection and monitoring 3.

Mineralocorticoid Receptor Antagonist (MRA)

Consider adding an MRA (spironolactone 12.5-25 mg daily or eplerenone 25 mg daily) if LVEF <40% to reduce mortality 2. Monitor potassium and renal function closely given her age.

Anticoagulation for COVID-19

Administer prophylactic-dose low-molecular-weight heparin (LMWH) during hospitalization 1. The 2023 CHEST guidelines recommend continuing antiplatelet therapy and adding prophylactic-dose LMWH for hospitalized COVID-19 patients with recent ACS 1.

• Use enoxaparin 40 mg subcutaneously daily (adjust for renal function—calculate creatinine clearance)
• Continue throughout hospitalization
• Do not escalate to therapeutic-dose anticoagulation unless specific indication (e.g., pulmonary embolism) emerges, as this significantly increases bleeding risk with concurrent DAPT 1

COPD Exacerbation Management

Bronchodilators

• Short-acting beta-agonist (albuterol) via nebulizer or inhaler every 4-6 hours as needed
• Short-acting anticholinergic (ipratropium) can be added for severe exacerbations
• Continue or optimize long-acting bronchodilators (LABA/LAMA combination) once acute phase resolves

Corticosteroids

Administer systemic corticosteroids for COPD exacerbation (prednisone 40 mg daily for 5 days). This does not contraindicate COVID-19 treatment and may actually be beneficial in severe COVID-19.

Antibiotics

Consider antibiotics if purulent sputum or clinical signs of bacterial infection (e.g., azithromycin 500 mg day 1, then 250 mg daily for 4 days).

Gastroprotection

Prescribe a proton pump inhibitor (omeprazole 20 mg daily or pantoprazole 40 mg daily) given her high gastrointestinal bleeding risk with DAPT at age 82 2. This is a class I recommendation for patients on DAPT at high bleeding risk.

Critical Monitoring Parameters

• Renal function: Calculate creatinine clearance (Cockcroft-Gault) for medication dosing—essential at age 82
• Potassium levels: Monitor closely with ACE inhibitor/ARB and potential MRA
• Bleeding signs: Daily assessment given DAPT plus anticoagulation
• Respiratory status: Monitor for beta-blocker-induced bronchospasm
• Troponin trends: Distinguish true ACS from COVID-19-related myocardial injury 1

Common Pitfalls to Avoid

1. Do not withhold DAPT due to COVID-19 status—the evidence shows no increased mortality with antiplatelet therapy in COVID-19 patients with ACS 1
2. Do not use therapeutic-dose anticoagulation routinely—reserve for specific indications as bleeding risk is prohibitive with DAPT 1
3. Do not avoid beta-blockers solely due to COPD—use cardioselective agents cautiously 3
4. Do not underdose medications due to age alone—adjust for renal function, not chronological age
5. Ensure creatinine clearance calculation for all renally cleared medications (enoxaparin, P2Y12 inhibitors)

The evidence strongly supports that COVID-19 does not fundamentally alter NSTEMI management 1. The key is balancing thrombotic risk (very high post-NSTEMI) against bleeding risk (elevated with age, DAPT, and anticoagulation) through careful medication selection and monitoring.